Indicators
Indicators
Value
Direction
MACD(12,26,9)
-4.395
Sell
RSI(14)
44.177
Neutral
STOCH(KDJ)(9,3,3)
41.115
Buy
ATR(14)
10.562
High Vlolatility
CCI(14)
-42.947
Neutral
Williams %R
60.101
Sell
TRIX(12,20)
-0.363
Sell
StochRSI(14)
100.000
Buy
Beigene Ltd
ONC316.050USD
+9.030+2.94%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
32.16BMarket Cap
513.88P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Beigene Ltd
Currency: USD Updated: 2025-12-19Key Insights
Beigene Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 390.24.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beigene Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
24
analysts
Buy
Current Rating
390.243
Target Price
+19.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Beigene Ltd Highlights
StrengthsRisks
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 169.10% year-on-year.
Overvalued
The company’s latest PE is 513.88, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.04M shares, decreasing 5.01% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 307.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Beigene Ltd is 9.47, ranking 4/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.41B, representing a year-over-year increase of 41.00%, while its net profit experienced a year-over-year increase of 202.88%.
Score
Financials
9.59
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.77
Beigene Ltd's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Beigene Ltd is 7.49, ranking 119/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 513.88, which is 19.43% below the recent high of 613.74 and 140.68% above the recent low of -209.02.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 40/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Beigene Ltd is 8.25, ranking 152/404 in the Biotechnology & Medical Research industry. The average price target for Beigene Ltd is 396.00, with a high of 448.00 and a low of 250.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
24
analysts
Buy
Current Rating
390.243
Target Price
+19.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Beigene Ltd
ONC
24
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Beigene Ltd is 7.04, ranking 160/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 348.57 and the support level at 291.52, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
308.820
Buy
MA10
315.186
Buy
MA20
325.333
Sell
MA50
327.655
Sell
MA100
324.779
Sell
MA200
288.911
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Beigene Ltd is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 36.51%, representing a quarter-over-quarter decrease of 36.55%. The largest institutional shareholder is PRIMECAP Management, holding a total of 5.08M shares, representing 4.63% of shares outstanding, with 0.40% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Amgen Inc
Baker Bros. Advisors LP
Capital International Investors
Fidelity Management & Research Company LLC
HHLR Advisors, Ltd.
Temasek Holdings Pte. Ltd.
T. Rowe Price International Ltd
Invus Public Equities Advisors, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Beigene Ltd is 6.77, ranking 25/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.48
VaR
+5.21%
240-Day Maximum Drawdown
+25.89%
240-Day Volatility
+52.91%
Return
Best Daily Return
60 days
+9.84%
120 days
+9.84%
5 years
+25.12%
Worst Daily Return
60 days
-4.68%
120 days
-10.59%
5 years
-15.71%
Sharpe Ratio
60 days
-0.26
120 days
+1.45
5 years
+0.28
Risk Assessment
Maximum Drawdown
240 days
+25.89%
3 years
+51.45%
5 years
+69.96%
Return-to-Drawdown Ratio
240 days
+2.90
3 years
+0.17
5 years
-0.01
Skewness
240 days
+0.16
3 years
+0.34
5 years
+0.55
Volatility
Realised Volatility
240 days
+52.91%
5 years
+59.74%
Standardised True Range
240 days
+3.40%
5 years
+3.32%
Downside Risk-Adjusted Return
120 days
+244.65%
240 days
+244.65%
Maximum Daily Upside Volatility
60 days
+37.89%
Maximum Daily Downside Volatility
60 days
+36.01%
Liquidity
Average Turnover Rate
60 days
+0.03%
120 days
+0.03%
5 years
--
Turnover Deviation
20 days
+5.37%
60 days
+15.27%
120 days
+25.43%
Peer Comparison
Biotechnology & Medical Research
Beigene Ltd
ONC
7.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Beigene Ltd?
The TradingKey Stock Score provides a comprehensive assessment of Beigene Ltd based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Beigene Ltd’s performance and outlook.
How do we generate the financial health score of Beigene Ltd?
To generate the financial health score of Beigene Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Beigene Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Beigene Ltd.
How do we generate the company valuation score of Beigene Ltd?
To generate the company valuation score of Beigene Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Beigene Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Beigene Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Beigene Ltd.
How do we generate the earnings forecast score of Beigene Ltd?
To calculate the earnings forecast score of Beigene Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Beigene Ltd’s future.
How do we generate the price momentum score of Beigene Ltd?
When generating the price momentum score for Beigene Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Beigene Ltd’s prices. A higher score indicates a more stable short-term price trend for Beigene Ltd.
How do we generate the institutional confidence score of Beigene Ltd?
To generate the institutional confidence score of Beigene Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Beigene Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Beigene Ltd.
How do we generate the risk management score of Beigene Ltd?
To assess the risk management score of Beigene Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Beigene Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Beigene Ltd.
